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Abstract: The wake-promoting agent modaﬁ  nil is approved for the treatment of excessive 
sleepiness associated with obstructive sleep apnea (OSA), shift work disorder (SWD), and 
narcolepsy. In OSA, modaﬁ  nil is recommended for use as an adjunct to standard therapies 
that treat the underlying airway obstruction. This article reviews the literature on modaﬁ  nil 
(pharmacology, pharmacokinetics, efﬁ  cacy, tolerability, and abuse potential), with emphasis on 
use of modaﬁ  nil in the treatment of excessive sleepiness in patients with OSA, SWD, and narco-
lepsy. In large-scale, double-blind, placebo-controlled studies, modaﬁ  nil improved objectively 
determined sleep latency, improved overall clinical condition related to severity of sleepiness, 
and reduced patient-reported sleepiness. Improvements in wakefulness were accompanied by 
improvements in behavioral alertness, functional status, and health-related quality of life. In 
patients with SWD, diary data showed modaﬁ  nil reduced the maximum level of sleepiness 
during night shift work, level of sleepiness during the commute home, and incidence of acci-
dents or near-accidents during the commute home when compared with placebo. Modaﬁ  nil 
was well tolerated, without adversely affecting cardiovascular parameters or scheduled sleep. 
These ﬁ  ndings and those of extension studies which reported improvements were maintained 
suggest modaﬁ  nil has a beneﬁ  cial effect on daily life and well-being in patients with excessive 
sleepiness associated with OSA, SWD, or narcolepsy.
Keywords: modaﬁ  nil, excessive sleepiness, wakefulness, obstructive sleep apnea, shift work 
disorder, narcolepsy
Introduction
Modaﬁ  nil, an orally administered wake-promoting agent, is indicated to improve 
wakefulness in adults with excessive sleepiness associated with obstructive sleep 
apnea (OSA), shift work disorder (SWD), and narcolepsy (PROVIGIL® 2007). In 
patients with OSA, modaﬁ  nil is recommended for use as an adjunct to standard thera-
pies prescribed for the underlying airway obstruction (PROVIGIL® 2007). Modaﬁ  nil 
was ﬁ  rst approved in the United States in December 1998 for use in narcolepsy and 
subsequently in January 2004 for use in OSA and SWD. This article reviews the litera-
ture on modaﬁ  nil (pharmacology, pharmacokinetics, efﬁ  cacy, tolerability, and abuse 
potential), with emphasis on use of modaﬁ  nil in the treatment of excessive sleepiness 
in patients with OSA, SWD, and narcolepsy.
Excessive sleepiness
Excessive sleepiness is the inability to remain awake during situations when wake-
fulness and alertness are required or expected (Arand et al 2005; Wise 2006). It is a 
main presenting symptom of individuals seen in sleep clinics and affects a substantial 
proportion of the general population. In a survey conducted by the National Sleep 
Foundation, 37% of adults reported sleepiness severe enough to interfere with activities 
of daily living a few days or more each month; 16% of respondents indicated exces-
sive sleepiness interfered with activities even more frequently (ie, a few days or more 
each week) (National Sleep Foundation 2002). Objective and subjective assessments Drug Design, Development and Therapy 2008:2 72
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of sleepiness in community-based samples suggest a preva-
lence of 24%–36% (Baldwin et al 2004; Mignot et al 2006; 
Singh et al 2006). Causes of excessive sleepiness include 
inadequate restorative sleep due to shortened duration or 
fragmentation, circadian rhythm disturbance or misalign-
ment, dysregulation of intrinsic mechanisms responsible for 
promoting sleep and wakefulness, and the use of sedating 
medications (Roth and Roehrs 1996). Excessive sleepiness 
is a prominent symptom of various disorders of sleep and 
wakefulness (American Academy of Sleep Medicine 2001) 
and of other medical and psychiatric disorders.
In addition to impairing physical, cognitive, and psycho-
social functioning, excessive sleepiness compromises the 
safety of individuals and the public at large. Sleepiness has 
been implicated in serious incidents in the workplace (Mitler 
et al 1988; Dinges 1995), and chronic sleepiness appears 
to be a signiﬁ  cant independent risk factor for involvement 
in vehicular accidents (Gander et al 2004). A recent cross-
sectional survey found road accidents due to sleepiness are 
not limited to commercial drivers during the night or early 
morning hours; near-miss accidents due to sleepiness are 
common among other types of drivers and appear to predict 
who is at risk for any type of actual accident (Powell et al 
2007). Individuals with disorders of sleep and wakefulness 
who have sleepiness as a prominent characteristic are among 
those who are at increased risk for sleep-related accidents 
(Lyznicki et al 1998; MacLean et al 2003; Drake et al 2004; 
Powell et al 2007).
Disorders of sleep and wakefulness: 
obstructive sleep apnea, shift work 
disorder, and narcolepsy
These three sleep disorders, though differing in origin, are 
all distinguished by excessive sleepiness. OSA affects an 
estimated 2%–4% of middle-aged adults (Young et al 1993). 
This chronic disorder is characterized by repeated episodes 
of partial or complete collapse of the upper airway during 
sleep. The partial or complete obstruction causes recurrent 
breathing difﬁ  culties, which are associated with arousals 
that disrupt sleep and may also cause hypoxemia. Elevated 
homeostatic sleep pressure and possibly hypoxic brain injury 
(Gale and Hopkins 2004; Veasey et al 2004; Morrell and 
Twigg 2006; Polotsky et al 2006; Zhu et al 2007) contribute 
to excessive sleepiness and other neurobehavioral and neuro-
psychological impairments in these patient. Nasal continuous 
positive airway pressure (CPAP) is an effective intervention 
for OSA (Engleman et al 1994a) that works to restore patency 
by pneumatically splinting the airway. However, clinically 
signiﬁ  cant excessive sleepiness may persist for some patients 
who regularly use CPAP therapy (Sforza and Krieger 1992). 
In patients with severe OSA and daytime sleepiness who 
were optimally treated with CPAP therapy (6 or more hours 
nightly), 8 of 36 patients (22%) subjectively reported ongo-
ing daytime sleepiness (assessed by the Epworth Sleepiness 
Scale), and 12 of 23 patients (52%) had ongoing objectively 
determined sleepiness (assessed by the MSLT) despite opti-
mal CPAP therapy (Weaver et al 2007).
SWD is a circadian rhythm sleep disorder estimated to 
affect 32% and 26% of night shift and rotating shift workers, 
respectively (Drake et al 2004). The disorder is caused by 
an inability to adapt internally driven processes that regulate 
sleep and wakefulness (ie, circadian cycles and homeostatic 
sleep drive) to externally imposed sleep-wake schedules. 
Minimal criteria for a diagnosis of SWD are a primary 
complaint of excessive sleepiness or insomnia and tempo-
ral association of symptoms with work that occurs during 
the period of habitual sleep (American Academy of Sleep 
Medicine 2001). Individuals with SWD have a signiﬁ  cantly 
greater risk for morbidity (ie, ulcers and depression) than shift 
workers without SWD or day workers who have identical 
symptoms (Drake et al 2004).
Narcolepsy is a chronic disorder of sleep/wake regula-
tion characterized by excessive sleepiness and symptoms 
of dissociated rapid eye movement sleep (ie, sleep attacks, 
cataplexy, hypnagogic hallucinations, and sleep paralysis). 
With the exception of excessive sleepiness, which occurs 
in 100% of patients, symptoms vary both in frequency and 
severity among individuals with the disorder. Narcolepsy 
with cataplexy is the most common variant, with an estimated 
prevalence of 0.02% to 0.18% (Mignot 1998). Narcolepsy 
with cataplexy is associated with a deﬁ  ciency of orexin-A, 
also known as hypocretin-1, a hypothalamic peptide impli-
cated in energy homeostasis and arousal (Sakurai 2007).
Chemistry and preclinical 
pharmacology
Modafinil is a benzyhydrylsulfinylacetamide derivative 
with a molecular formula of C15H15NO2S. It is chemically 
unrelated to and pharmacologically distinguishable from 
the central nervous system (CNS) stimulants (eg, dextro-
amphetamine and methylphenidate) (Duteil et al 1990; Lin 
et al 1992, 1996; Simon et al 1994, 1995; Shelton et al 1995; 
Florence et al 2000). The primary pharmacological activ-
ity of modaﬁ  nil is promoting wakefulness. Modaﬁ  nil has 
been shown to increase wakefulness in studies conducted 
in animal models of narcolepsy (Shelton et al 1995) and Drug Design, Development and Therapy 2008:2 73
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sleep-disordered breathing (Panckeri et al 1996) and in sleep-
deprived human volunteers (Lagarde et al 1995; Pigeau et al 
1995; Walsh et al 2004).
Identification of the specific molecular targets that 
underlie the wake-promoting activity of modaﬁ  nil is ongo-
ing. In vitro, modaﬁ  nil interacted negligibly or weakly with 
receptors for adenosine, dopamine, serotonin, histamine, 
melatonin, γ-amino butyric acid (GABA), and benzodiaz-
epines (Mignot et al 1994; PROVIGIL® 2007). Modaﬁ  nil 
has not been shown to be an α1-adrenergic agonist, although 
animal studies suggest an intact α1-adrenergic system may 
be necessary for modaﬁ  nil-induced increases in locomotor 
activity (Duteil et al 1990; Hermant et al 1991; Lin et al 
1992). In contrast to amphetamine, modaﬁ  nil-induced wake-
fulness was not blocked by a dopamine-receptor antagonist 
or substantially affected by administration of an inhibi-
tor of catecholamine synthesis (Lin et al 1992). In vitro, 
modaﬁ  nil has been shown to bind weakly but selectively to 
the dopamine transporter (Mignot et al 1994; Nishino et al 
1998; Madras et al 2006) and, to a lesser extent, the norepi-
nephrine transporter (Madras et al 2006). Wake-promoting 
concentrations of modaﬁ  nil increased extracellular levels 
of monoamines, including norepinephrine and dopamine, 
in certain rat brain regions (de Saint Hilaire et al 2001). 
Mutant mice lacking the dopamine transporter gene were 
unresponsive to modaﬁ  nil (Wisor et al 2001). Studies in 
animals suggest modaﬁ  nil increases activity in the cortex 
through selective actions on hypothalamic regions involved 
in regulating sleep and wakefulness. In a study that evalu-
ated c-fos expression in cat brain, modaﬁ  nil discretely and 
differentially from amphetamine and methylphenidate acti-
vated areas of the hypothalamus implicated in maintaining 
normal wakefulness, including the anterior hypothalamic 
nucleus and surrounding areas, with labeling of few cells in 
the cortex (Lin et al 1996). The authors suggested modaﬁ  nil 
may promote wakefulness by disinihibiting cortical neurons. 
Another study reported intraperitoneal administration of 
wake-promoting doses of modaﬁ  nil in rats induced c-fos 
expression in orexin neurons in the perifornical lateral hypo-
thalamus and also increased c-fos in the tuberomammillary 
nucleus (TMN) of the posterior hypothalamus (Scammell 
et al 2000). The TMN is the source of central histaminergic 
neurons, which are active during waking and mediate corti-
cal arousal (Lin et al 1988, 1990, 1994; Lin 2000). The study 
also reported modaﬁ  nil decreased activity in the ventrolat-
eral preoptic nucleus (VLPO), a sleep-promoting region of 
the hypothalamus. The VLPO is active during sleep and 
provides inhibitory GABA-ergic input to neurons involved 
in wakefulness (Sherin et al 1996, 1998; Gallopin et al 
2000). Modaﬁ  nil also increased activity in cortical regions, 
including the frontal and cingulate cortex, compared with 
controls. In another study, intracerebroventricular injection 
of modaﬁ  nil increased histamine release in anesthetized rats 
whereas direct injection into the tuberomammillary nucleus 
did not, suggesting histaminergic neurons were not directly 
targeted (Ishizuka et al 2003). Others have shown modaﬁ  nil 
may potentiate the sleep-inhibiting activity of noradrenaline 
in the VLPO (Gallopin et al 2004). These ﬁ  ndings sug-
gest modaﬁ  nil may promote wakefulness, at least in part, 
by indirectly activating ascending arousal systems via an 
inhibitory action on sleep-active neurons (Gallopin et al 
2004). This action is consistent the ﬁ  nding that modaﬁ  nil is 
not associated with rebound hypersomnolence (Edgar and 
Seidel 1997; Lin et al 2000).
Clinical pharmacokinetics
Modaﬁ  nil is a racemic compound, with two enantiomers 
that are pharmacokinetically dissimilar. The R-enantiomer 
has a longer half-life than the S-enantiomer (10–14 h vs 
3–4 h) (Wong et al 1999a; Wong et al 1999b; Robertson 
and Hellriegel 2003), and the S-enantiomer has a faster 
rate of clearance (Wong et al 1999b). The enantiomers 
have similar pharmacological properties, but because total 
exposure of R-modaﬁ  nil is approximately 3 times that of S-
modaﬁ  nil, wake-promoting activity is likely due primarily 
to the R-enantiomer (Dinges et al 2006). The R-enantiomer, 
also known as armodaﬁ  nil, has recently been approved to 
treat excessive sleepiness associated with OSA, SWD, and 
narcolepsy (NUVIGIL® 2007), but is not yet commercially 
available. The effective elimination half-life of racemic 
modaﬁ  nil allows once-daily dosing.
Orally administered modaﬁ  nil is absorbed readily, with 
maximum plasma concentrations (Cmax) occurring at 2–4 
hours (Robertson and Hellriegel 2003). Absorption (tmax) 
may be delayed by approximately 1 hour if modaﬁ  nil is taken 
with food (PROVIGIL 2007). Steady-state plasma concen-
trations are reached within 4 days of dosing (Robertson and 
Hellriegel 2003). Modaﬁ  nil is well distributed in body tissue, 
with an apparent volume of distribution of 0.8 L/kg (Wong 
et al 1999a). Metabolism (90%) occurs primarily through the 
liver, with renal elimination of metabolites (Robertson and 
Hellriegel 2003). Less than 10% of the administered dose is 
excreted in urine as unchanged drug (Robertson and Hellr-
iegel 2003). Two metabolites, modaﬁ  nil acid and modaﬁ  nil 
sulfone, reach appreciable levels in plasma (PROVIGIL® 
2007; Robertson and Hellriegel 2003). Modaﬁ  nil acid is Drug Design, Development and Therapy 2008:2 74
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the major urinary metabolite (Wong et al 1999a). Neither 
metabolite appears to contribute to the wake-promoting 
activity of modaﬁ  nil (Robertson and Hellriegel 2003).
The pharmacokinetics of modaﬁ  nil is not affected by 
gender, but oral clearance (CL/F) of modaﬁ  nil may be 
reduced in elderly patients (Wong et al 1999b). Severe 
chronic renal failure was not shown to signiﬁ  cantly affect 
the pharmacokinetics of modaﬁ  nil, but plasma concentra-
tions of an inactive metabolite increased 9-fold (PROVIGIL® 
2007). In patients with cirrhosis of the liver, oral clearance 
of modaﬁ  nil was decreased by ~60%, and steady state 
concentration was doubled compared with healthy subjects 
(PROVIGIL® 2007). Adjustments in dosing should be 
considered for these patient populations (Robertson and 
Hellriegel 2003; PROVIGIL® 2007).
Drug – drug interactions
Modaﬁ  nil has the potential to modulate the activities of 
hepatic cytochrome P450 (CYP) isoenzymes. In human 
liver microsomes, modaﬁ  nil reversibly inhibited CYP2C19 
(Robertson et al 2000). Because of its potential to inhibit 
CYP2C19, modaﬁ  nil may prolong elimination and increase 
circulating levels of drugs that are primarily metabolized via 
this enzyme (eg, diazepam, phenytoin, and propranolol). 
Dose reduction and toxicity monitoring may be required 
when drugs metabolized by CYP2C19 are coadministered 
with modaﬁ  nil (Robertson et al 2000; PROVIGIL® 2007). In 
individuals who are deﬁ  cient in CYP2D6, coadministration 
of modaﬁ  nil with substrates of CYP2D6 that have ancil-
lary routes of elimination through CYP2C19 (eg, tricyclic 
antidepressants and selective serotonin reuptake inhibitors) 
may lead to elevated circulating levels of these drugs and 
require dose adjustment (Robertson et al 2000; PROVIGIL® 
2007). Modaﬁ  nil suppressed CYP2C9 activity in cultures 
of human hepatocytes, suggesting a potential for drug 
interactions between modaﬁ  nil and enzyme substrates (eg, 
S-warfarin, phenytoin) (Robertson et al 2000). Despite this 
in vitro ﬁ  nding, modaﬁ  nil administration for 4 weeks did 
not signiﬁ  cantly alter the pharmacokinetics of S-warfarin, 
a substrate for CYP2C9, compared with placebo in a study 
of healthy volunteers who were given a single dose of 
racemic warfarin following long-term administration of 
modaﬁ  nil (Robertson et al 2002a). Because potential inter-
actions between warfarin and other agents have also been 
documented, increased monitoring of prothrombin times/
International Normalized Ratio is recommended whenever 
modaﬁ  nil and warfarin are coadministerered (Robertson 
et al 2000; PROVIGIL® 2007).
Modaﬁ  nil also has been shown to cause a modest induction 
of CYP3A4, CYP2B6, and CYP1A2 in human hepatocytes 
(Robertson et al 2000). Protracted daily administration of 
modaﬁ  nil (400 mg) decreased systemic exposure of orally 
administered triazolam and ethinyl estradiol, two substrates 
of CYP3A4, suggesting increased elimination (Robertson 
et al 2002b). Dose adjustments may be necessary for patients 
taking these and similar medications (PROVIGIL® 2007). 
Because the effectiveness of steroidal contraceptives may 
be reduced when taken concurrently with modaﬁ  nil, addi-
tional or alternative methods of contraception should be 
used during treatment with modaﬁ  nil and for 1 month after 
discontinuation of modaﬁ  nil therapy (Robertson et al 2002b; 
PROVIGIL® 2007).
Modaﬁ  nil is partially metabolized by CYP3A4. Coadmin-
istration of potent inducers (eg, carbamazepine, phenobarbi-
tal, rifampin) or inhibitors (eg, ketoconazole, itraconazole) 
of this enzyme may modify modaﬁ  nil levels in plasma 
(PROVIGIL® 2007).
Clinical efﬁ  cacy and tolerability: 
overview of double-blind
placebo-controlled studies
The efficacy and tolerability of once-daily doses 
(200–400 mg) of modaﬁ  nil were established in large-
scale, double-blind, placebo-controlled clinical studies 
conducted in patients with OSA (Pack et al 2001; Black 
and Hirshkowitz 2005), SWD (Czeisler et al 2005; Erman 
et al 2007), and narcolepsy (US Modaﬁ  nil in Narcolepsy 
Multicenter Study Group 1998, 2000). In ﬁ  ve of the six 
studies, an objective measure of excessive sleepiness/
sleep latency – the Multiple Sleep Latency Test (MSLT) 
(Carskadon et al 1986) or the Maintenance of Wakefulness 
Test (MWT) (Mitler et al 1982; Doghramji et al 1997) – was 
chosen prospectively as a primary efﬁ  cacy measure. The 
MSLT and MWT measure the propensity of individuals to 
fall asleep or remain awake, respectively, when instructed 
to do so in a formalized laboratory setting. Another 
primary end point was the investigator-rated change in 
overall clinical condition for severity of sleepiness (ie, 
the Clinical Global Impression of Change [CGI-C] [Guy 
1976]). All six studies evaluated tolerability and safety of 
modaﬁ  nil administered for 4–12 weeks.
The studies also evaluated subjectively determined 
sleepiness with the use of the Epworth Sleepiness Scale 
(ESS) (Johns et al 1991) or the Karolinska Sleepiness Scale 
(KSS) (Akerstedt et al 1982). The 8-item ESS was used in 
the OSA and narcolepsy studies to determine the extent to Drug Design, Development and Therapy 2008:2 75
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which excessive sleepiness interfered with daily activities. 
The 9-item KSS was used in a SWD study (Czeisler et al 
2005) because of its widespread use in the assessment of 
excessive sleepiness in circadian rhythm sleep disorders. 
Other assessments included the Psychomotor Vigilance Task 
(PVT) (Dinges and Powell 1985), a test of sustained atten-
tion performance that was used to assess behavioral alertness 
(OSA and SWD studies); the Functional Outcomes of Sleep 
Questionnaire (FOSQ) (Weaver et al 1997), a self-adminis-
tered 30-item instrument that was used to determine the effect 
of excessive sleepiness on functional status (OSA and SWD 
studies); and the 36-item Short Form Health Survey (SF-36) 
(Ware 2007), a self-administered questionnaire that assessed 
health-related quality of life (OSA, SWD, and narcolepsy 
studies). Patients with SWD completed electronic diaries that 
contained questions about sleepiness, sleep, and caffeine use 
during the night shift and on the commute home.
Patients enrolled in these studies had a diagnosis of OSA, 
SWD, or narcolepsy and were required to meet accepted cri-
teria for excessive sleepiness. In the OSA studies, study drug 
was administered in conjunction with ongoing CPAP therapy. 
Patients were men and women (24–76 years) with a diagnosis 
of OSA and evidence of residual excessive sleepiness (ie, 
screening/baseline ESS score of  10) despite CPAP use (ie, 
apnea-hypopnea index [AHI] of  10). In the 4-week study, 
157 patients were randomly assigned to receive modaﬁ  nil 
(week 1, 200 mg/day; weeks 2–4, 400 mg/day) or matching 
placebo once daily after the morning meal (Pack et al 2001). 
In the 12-week study, 309 patients were randomly assigned 
to receive modaﬁ  nil 200 mg, modaﬁ  nil 400 mg, or matching 
placebo once daily in the morning (Black and Hirshkowitz 
2005). The starting dose was 100 mg, which was increased 
by 100-mg increments every 2 days until the ﬁ  nal dose was 
reached.
In the SWD studies, men and women (18–60 years) who 
were diagnosed with SWD and had excessive sleepiness 
during the night shift were eligible. In one of the studies, 
patients had to have a mean sleep latency of  6 minutes 
on a night-time MSLT (Czeisler et al 2005). A total of 209 
patients were randomly assigned to receive modaﬁ  nil 200 
mg once daily or placebo, taken 1 hour before the start of 
the night shift. In another 12-week study, 278 patients were 
randomized to receive modaﬁ  nil 200 mg, modaﬁ  nil 300 mg, 
or placebo 30–60 minutes before each night shift (Erman 
et al 2007).
In the narcolepsy studies, men and women (17–68 years) 
with a diagnosis of narcolepsy had sleep latencies of  8 
minutes (for those with recurrent daytime naps or lapses into 
sleep that were occurring almost daily for at least 3 months, 
with cataplexy) or  5 minutes (for those with a complaint of 
excessive sleepiness or sudden muscle weakness, with sleep 
paralysis, hypnagogic hallucinations, automatic behaviors, 
and disrupted major sleep episode). Patients had to have 2 
or more sleep-onset, rapid-eye-movement periods during 
administration of the MSLT. Patients (n = 285 and n = 273) 
were randomly assigned to receive once-daily modaﬁ  nil 
200 mg/day, modaﬁ  nil 400 mg/day, or placebo for 9 weeks 
using a rapid dose-titration schedule (US Modaﬁ  nil in Nar-
colepsy Multicenter Study Group 1998) or a gradual step-up 
protocol (US Modaﬁ  nil in Narcolepsy Multicenter Study 
Group 2000).
The 3 study populations were similar with regard 
to demographic characteristics (Table 1). There were 
proportionally more men than woman in the OSA studies, 
in keeping with the known epidemiology of the disorder. 
Most patients were rated as at least moderately ill with 
regard to sleepiness on the Clinical Global Impression of 
Severity. Patients were moderately to severely sleepy at 
baseline. In one study, mean sleep latency on the MSLT 
averaged approximately 2 minutes for patients with SWD 
(Czeisler et al 2005). In another study, mean sleep latency 
was 7.5 minutes for patients with OSA (Pack et al 2001). 
Sleep latencies of 5 minutes or less are indicative of severe 
sleepiness (Carskadon et al 1986; American Academy of 
Sleep Medicine 2001).
Efﬁ  cacy outcomes
OSA studies
In the 4-week study, modafinil significantly improved 
objectively determined wakefulness and reduced patient-
reported sleepiness (MSLT and ESS, respectively) compared 
with placebo (Table 2) (Pack et al 2001). At week 4, 51% 
of patients receiving modaﬁ  nil had excessive sleepiness that 
normalized (ie, ESS score  10) compared with 27% of patients 
receiving placebo (p   0.01). Signiﬁ  cant improvements were 
shown for patients receiving modaﬁ  nil compared with patients 
receiving placebo in 4 of 14 PVT performance variables, 
including the number of lapses (transformed) andthe median 
reaction time (Table 2) (Dinges and Weaver 2003). Modaﬁ  nil 
improved functional status on the FOSQ, with signiﬁ  cant 
improvements in the total score and 2 of 5 subscales (ie, 
activity and vigilance)  versus placebo after 4 weeks. 
Modaﬁ  nil signiﬁ  cantly improved overall clinical condition for 
sleepiness, with 71% of patients receiving modaﬁ  nil rated by 
the investigator as improved compared with 35% of patients 
receiving placebo (p   0.05) (Pack et al 2001).Drug Design, Development and Therapy 2008:2 76
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In the 12-week study, modaﬁ  nil signiﬁ  cantly improved 
objectively determined wakefulness on the MWT, reduced 
sleepiness levels on the ESS, and improved the FOSQ total 
score and subscale scores for vigilance, general productivity, 
and activity but not scores for social outcome or intimacy 
(Table 2) (Black and Hirshkowitz 2005). At week 12, overall 
clinical condition improved for 61% and 68% of patients 
receiving modaﬁ  nil 200 mg and 400 mg, respectively, com-
pared with 37% of patients receiving placebo (p   0.001) 
(Black and Hirshkowitz 2005).
SWD studies
In one 12-week study, modafinil 200 mg significantly 
improved nighttime sleep latency on the MSLT, reduced 
levels of sleepiness on the KSS, and reduced the frequency 
of performance lapses on the PVT (Table 3) (Czeisler et al 
2005). A greater proportion of patients receiving modaﬁ  nil 
were rated as improved at the ﬁ  nal visit on the CGI-C than 
patients receiving placebo (74% vs 36%) (p   0.001). As 
reported in patient diaries, modaﬁ  nil 200 mg reduced the 
maximum level of sleepiness during night shift work com-
pared with placebo (mean change from baseline, –1.9 [1.4] vs 
–0.9 [1.0]) (p   0.001) and the level of sleepiness during the 
commute home (–1.1 [1.5] vs –0.6 [1.2]) (p = 0.01). Fewer 
patients receiving modaﬁ  nil than placebo reported having 
accidents or near accidents on the commute home (29% 
vs 54%) (p   0.001). Modaﬁ  nil was not associated with 
statistically signiﬁ  cant effects on unintentional or intentional 
sleep episodes, caffeine intake, or mistakes, accidents, or 
near accidents during night shifts. During days following 
nights when the night shifts were not worked, no differences 
were reported in caffeine use or sleep efﬁ  ciency between 
modaﬁ  nil and placebo.
In another 12-week study, modaﬁ  nil improved aspects 
of daily functioning and health-related quality of life the 
day after shifts compared with placebo (Table 3) (Erman 
et al 2007). The FOSQ total score was significantly 
improved with modafinil 300 mg, as were vigilance, 
activity, and productivity subscale scores. No signiﬁ  cant 
improvement was shown with modaﬁ  nil 300 mg in social 
outcome or intimacy. Modafinil 200 mg significantly 
improved the activity subscale score compared with pla-
cebo. Signiﬁ  cant improvements were shown for the SF-36 
mental component score and the vitality and role-emotional 
domain scores.
Narcolepsy studies
In both studies, modaﬁ  nil 200 and 400 mg signiﬁ  cantly 
improved objectively determined sleep latency (MSLT and 
MWT) and subjectively assessed sleepiness levels (ESS) 
compared with placebo (Table 4) (US Modaﬁ  nil in Nar-
colepsy Multicenter Study Group 1998, 2000). Modaﬁ  nil 
signiﬁ  cantly improved health-related quality of life on the 
SF-36 compared with placebo, with greater vitality, fewer 
constraints on daily activities due to physical or emotional 
limitations, and less interference with social activities due 
Table 1 Demographic characteristics and illness severity ratings at baseline for patients in large-scale, double-blind, placebo-controlled 
studies of modaﬁ  nil
Obstructive sleep apnea studies
n = 446a
Shift work disorder studies
n = 455a
Narcolepsy stud-
ies n = 530a
Mean (SD) age, yr 49.7 (9.4) 39.5 (9.2) 41.8 (13.3)
Gender, n (%)
Male 340 (76) 243 (53) 239 (45)
Female 106 (24) 212 (47) 291 (55)
Race, n (%)
White 396 (89) 321 (71) 434 (82)
Black 29 (7) 99 (22) 77 (15)
Other 21 (4) 34 (7) 19 (4)
CGI-S rating
Not recorded 43 (10) 0 (0) 0 (0)
Normal, mildly, or slightly ill 121 (27) 0 (0) 91 (17)
Moderately ill 199 (45) 280 (62) 237 (45)
Markedly, severely, or extremely ill 83 (19) 175 (38) 202 (38)
aPatients receiving one dose of study medication (modaﬁ  nil or placebo) who had at least one post-baseline follow-up.
Adapted from Schwartz 2005.
Abbreviations: SD, standard deviation; CGI-S, clinical global impression of severity.Drug Design, Development and Therapy 2008:2 77
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to health (Table 4) (Beusterien et al 1999). No signiﬁ  cant 
treatment effect was shown for physical functioning, bodily 
pain, general health, or mental health.
Tolerability and safety outcomes
In these double-blind placebo-controlled studies, 1501 
patients received 200, 300, or 400 mg of modaﬁ  nil (n = 934) 
or placebo (n = 567) for up to 12 weeks (Roth et al 2007). 
Safety was assessed in these studies by monitoring adverse 
events, vital signs (ie, resting systolic and resting diastolic 
blood pressures, heart rate, and body weight), electrocardio-
gram (ECG) intervals, clinical laboratory parameters, and 
polysomnographic parameters collected during the day (OSA 
and narcolepsy) or night (SWD). Across the studies, adverse 
event proﬁ  les were similar, with headache (34%), nausea 
(11%), infection (10%), nervousness (7%), rhinitis (7%), 
diarrhea (6%), back pain (6%), anxiety (5%), dizziness, (5%), 
dyspepsia (5%), and insomnia (5%) the most common treat-
ment-emergent adverse events ( Roth et al 2007). Headache 
was considered to be dose related (Roth et al 2007). Adverse 
events that occurred more frequently with modaﬁ  nil than pla-
cebo were headache, nausea, nervousness, anxiety, insomnia, 
anorexia, dry mouth, hypertension, and pharyngitis (p   0.05 
vs placebo) (Roth et al 2007). Most adverse events (nearly 
90%) occurred during the ﬁ  rst month and were considered by 
the investigator to be mild to moderate in nature (PROVIGIL® 
2007; Roth et al 2007). For the combined modaﬁ  nil group, the 
cumulative incidence of headache was 20% at week 1 (vs 9% 
for placebo), 29% at month 1 (vs 18% for placebo), and 34% 
at month 3 (vs 23% for placebo) (Roth et al 2007). Across 
the studies, 8% of patients receiving modaﬁ  nil discontinued 
because of an adverse event compared with 3% of patients 
receiving placebo (PROVIGIL® 2007; Roth et al 2007). The 
most frequently occurring adverse event associated with 
discontinuation was headache (2%) (Roth et al 2007).
Although a small but statistically signiﬁ  cant difference 
in the mean change from baseline in sitting systolic blood 
pressure was observed between modaﬁ  nil and placebo in the 
Table 3 Summary outcomes for patients receiving modaﬁ  nil or placebo in the SWD studies
Study/Reference Measure Treatment Mean (SD)
at baseline
Mean (SD)
at ﬁ  nal visit
Mean (SD) change 
from baseline
to ﬁ  nal visit
P-valuea
12-week study #1/
Czeisler et al 2005
MSLT sleep latency (min) Modaﬁ  nil 200 mg
Placebo
2.07 (0.2)
2.04 (0.2)
3.77 (0.5)
2.37 (0.3)
1.7 (0.4)
0.3 (0.3)
0.002
KSS score Modaﬁ  nil 200 mg
Placebo
7.3 (0.1)
7.1 (0.1)
5.8 (0.2)
6.7 (0.2)
–1.5 (0.2)
–0.4 (0.2)
 0.001
PVT number of lapses Modaﬁ  nil 200 mg
Placebo
12.50b
16.13b
10.25b
23.75b
–2.6c
3.8c
 0.001
12-week study #2/
Erman et al 2007
FOSQ total scored Modaﬁ  nil 300 mg
Placebo
2.3
1.6
 0.05
FOSQ vigilance Modaﬁ  nil 300 mg
Placebo
0.6
0.4
 0.05
FOSQ activity Modaﬁ  nil 200 mg
Placebo
0.5
0.3
 0.05
Modaﬁ  nil 300 mg
Placebo
0.5
0.3
 0.01
FOSQ productivity Modaﬁ  nil 300 mg
Placebo
0.4
0.3
 0.01
SF-36 mental component scoree Modaﬁ  nil 200 mg
Modaﬁ  nil 300 mg
Placebo
3.7
3.2
0.7
 0.05
 0.05
SF-36 vitality Modaﬁ  nil 200 mg
Modaﬁ  nil 300 mg
Placebo
15.0
14.8
5.3
 0.001
 0.0001
SF-36 role emotional Modaﬁ  nil 300 mg
Placebo
4.3
–2.9
 0.05
aFor the change from baseline for modaﬁ  nil versus placebo.
bMedian number of lapses.
cMedian change from baseline.
dFOSQ total scores at baseline were similar for modaﬁ  nil 200 mg, modaﬁ  nil 300 mg, and placebo (range: 14.3–14.7 points).
eSF-36 mental component scores at baseline were similar for the 3 groups (range: 45.3–47.4).
Abbreviations: SD, standard deviation; SWD, shift work disorder; MSLT, Multiple Sleep Latency Test; PVT, Psychomotor Vigilance Task; KSS, Karolinska Sleepiness Score; 
FOSQ, Functional Outcomes of Sleep Questionnaire; SF-36, 36-item Short Form Health Survey.Drug Design, Development and Therapy 2008:2 79
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4-week OSA study (Pack et al 2001), no signiﬁ  cant changes 
from baseline to ﬁ  nal visit in mean systolic blood pressure, 
diastolic blood pressure, or heart rate were shown between 
modaﬁ  nil and placebo for the combined OSA studies or the 
combined SWD studies (Roth et al 2007). In the combined 
narcolepsy studies, a signiﬁ  cant between-group difference 
in heart rate and blood pressure was demonstrated; the dif-
ference was attributable to a greater change from baseline 
for placebo than modaﬁ  nil (Roth et al 2007). A greater 
proportion of patients receiving modaﬁ  nil began treatment 
with or increased their use of antihypertensive medications 
compared with patients receiving placebo (2.4% vs 0.7%) 
(PROVIGIL® 2007; Roth et al 2007). When OSA data 
alone were included, 3.4% versus 1.1% of patients receiv-
ing modaﬁ  nil or placebo, respectively, required changes in 
the use of antihypertensive medications (PROVIGIL® 2007; 
Roth et al 2007). For some patients, increased blood pressure 
monitoring may be necessary.
Across the studies, no signiﬁ  cant changes from baseline 
were shown in mean body weight. Clinically signiﬁ  cant 
decreases in weight (ie,  7% from baseline) were reported 
for 3% of patients receiving modaﬁ  nil (Roth et al 2007). 
No treatment-emergent pattern of electrocardiographic 
abnormalities was found following modaﬁ  nil administration 
(PROVIGIL® 2007; Roth et al 2007). Mean plasma levels of 
gamma glutamyltransferase and alkaline phosphatase were 
Table 4 Summary outcomes for patients receiving modaﬁ  nil or placebo in the narcolepsy studies
Study/Reference Measure Treatment Mean (SD)
at baseline
Mean (SD)
at ﬁ  nal visit
Mean (SD) change
from baseline
to ﬁ  nal visit
P-valuea
9-week study #1/ US
Modaﬁ  nil in Narcolepsy 
Multicenter Study
Group 1998
MSLT sleep latency (min) Modaﬁ  nil 200 mg
Modaﬁ  nil 400 mg
Placebo
2.9 (2.5)
3.3 (2.9)
2.8 (2.2)
4.7 (4.4)
5.2 (4.5)
3.3 (3.2)
 0.001
 0.001
MWT sleep latency (min) Modaﬁ  nil 200 mg
Modaﬁ  nil 400 mg
Placebo
5.8 (5.0)
6.6 (5.2)
5.8 (4.7)
8.1 (6.1)
8.9 (6.2)
5.1 (4.7)
 0.001
 0.001
ESS score Modaﬁ  nil 200 mg
Modaﬁ  nil 400 mg
Placebo
17.9 (3.8)
17.1 (4.2)
18.3 (3.3)
14.4 (5.7)
13.0 (5.7)
17.1 (5.0)
 0.001
 0.001
9-week study #2/ US
Modaﬁ  nil in Narcolepsy
Multicenter Study
Group 2000
MSLT sleep latency (min) Modaﬁ  nil 200 mg
Modaﬁ  nil 400 mg
Placebo
3.0 (2.2)
2.7 (2.0)
2.2 (1.8)
4.9 (4.3)
5.1 (4.0)
3.5 (3.4)
 0.001
MWT sleep latency (min) Modaﬁ  nil 200 mg
Modaﬁ  nil 400 mg
Placebo
6.1 (4.9)
5.9 (4.4)
6.0 (5.0)
8.2 (5.9)
7.8 (5.3)
5.5 (4.5)
0.001
 0.001
ESS score Modaﬁ  nil 200 mg
Modaﬁ  nil 400 mg
Placebo
17.4 (3.8)
18.0 (3.4)
17.6 (4.0)
13.0 (5.1)
12.3 (5.1)
15.8 (4.8)
 0.001
 0.001
9-week studies
combined/Beusterien
et al 1999 SF-36 vitality Modaﬁ  nil 200 mg 11  0.05
Modaﬁ  nil 400 mg
Placebo
13
3
 0.05
SF-36 role limitations-
emotional
Modaﬁ  nil 200 mg
Modaﬁ  nil 400 mg
Placebo
6
10
–1
 0.05
SF-36 role limitations-
physical
Modaﬁ  nil 200 mg
Modaﬁ  nil 400 mg
Placebo
14
20
6
 0.05
 0.05
SF-36 social function Modaﬁ  nil 200 mg
Modaﬁ  nil 400 mg
Placebo
6
11
2
 0.05
aFor the change from baseline for modaﬁ  nil versus placebo.
Abbreviations: SD, standard deviation; MSLT, Multiple Sleep Latency Test; MWT, Maintenance of Wakefulness Test; ESS, Epworth Sleepiness Scale.Drug Design, Development and Therapy 2008:2 80
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higher following administration of modaﬁ  nil but not placebo 
(PROVIGIL® 2007; Roth et al 2007). Clinically signiﬁ  cant 
abnormalities in laboratory parameters were rare and reported 
in  1% of patients receiving modaﬁ  nil or placebo (Roth 
et al 2007).
In these studies, modaﬁ  nil did not adversely affect 
scheduled sleep. No clinically meaningful or statistically 
signiﬁ  cant differences shown between groups in polysom-
nographically determined sleep parameters, including sleep 
efﬁ  ciency, sleep duration, and stages of sleep (US Modaﬁ  nil 
in Narcolepsy Multicenter Study Group 1998, 2000; Pack 
et al 2001; Black and Hirshkowitz 2005, Czeisler et al 
2005). In the 4-week OSA study, mean arousal index (ie, the 
number of arousals per hour of sleep) was slightly greater 
for patients receiving modaﬁ  nil than patients receiving 
placebo (14.3 vs 11.8) (p = 0.018) (Pack et al 2001). In 
a 9-week narcolepsy study, sleep efﬁ  ciency was slightly 
better for the modaﬁ  nil 200-mg group than the placebo 
group (US Modaﬁ  nil in Narcolepsy Multicenter Study 
Group 2000). Modaﬁ  nil was not associated with symp-
toms of withdrawal (eg, fatigue, agitation, vivid dreams, 
hypersomnia, or increased appetite) when its use was dis-
continued for 2 weeks following 9 weeks of administration 
in patients with narcolepsy (US Modaﬁ  nil in Narcolepsy 
Multicenter Study Group 2000).
Additional safety data
More than 3500 patients have been evaluated for safety in 
clinical studies of modaﬁ  nil for treatment of excessive sleepi-
ness associated with OSA, SWD, and narcolepsy (Schwartz 
2005; PROVIGIL® 2007). The type and incidence of adverse 
events have been consistent with those reported in the pla-
cebo-controlled trials. Serious rash requiring hospitalization 
and treatment discontinuation have been reported in associa-
tion with modaﬁ  nil use (FDA 2007; PROVIGIL® 2007). In 
worldwide postmarketing experience, rare cases (exceeding 
the background incidence rate in the general population of 
1–2 cases per million-person years) of serious or life-threat-
ening rash, including Stevens-Johnson Syndrome, have been 
reported in adults and children. No factors are known that 
may be used to predict either rash occurrence or severity. It is 
recommended that modaﬁ  nil be discontinued at the ﬁ  rst sign 
of rash unless the rash is clearly not related to the drug.
Extension studies
An open-label extension of the 4-week OSA study reported 
improvements in wakefulness and sleep-related functional 
status were maintained for 12 additional weeks in patients 
receiving CPAP therapy (Schwartz et al 2003c). In a 
long-term open-label extension conducted in patients who 
participated in the 12-week OSA study, improvements in 
subjectively determined wakefulness, functional status, and 
health-related quality of life were maintained with modaﬁ  nil 
for 12 months (Schwartz 2005; Hirshkowitz and Black 2007). 
The extension study did not evaluate objectively determined 
sleep latency. Modaﬁ  nil continued to be well tolerated, with 
infection (11.3%), headache (9.4%), and nervousness (9.0%) 
being the most common adverse events reported (Hirshkowitz 
and Black 2007). Although no substantial alterations were 
reported in the mean change from baseline in blood pressure 
and heart rate, a clinically signiﬁ  cant elevation in blood pres-
sure was reported for 6 patients (2%) (at a single evaluation 
for 5 patients and at 2 consecutive evaluations for 1 patient). 
Five of these patients had a history of hypertension.
Patients from the narcolepsy studies participated in 
open-label extensions in which they received modaﬁ  nil 
200 mg to 400 mg once daily (Mitler et al 2000; Schwartz 
2005). Improvements in wakefulness with modaﬁ  nil were 
maintained through 136 weeks of open-label administration. 
Modaﬁ  nil was well tolerated, with a low likelihood for the 
development of tolerance.
Additional clinical studies
In addition to the large-scale placebo-controlled studies 
and long-term extension studies, other clinical studies and 
case reports have reported improvements in wakefulness 
with modaﬁ  nil in patients with OSA (Kingshott et al 2001; 
Schwartz et al 2003c) and narcolepsy (Billiard et al 1994; 
Besset et al 1996; Broughton et al 1997; Moldofsky et al 
2000; Thorpy et al 2003; Schwartz et al 2003a, b, 2004, 
2005). In a double-blind crossover study of 30 patients 
with OSA who were receiving CPAP therapy, modaﬁ  nil 
had no effect on sleepiness as assessed on the MSLT or the 
ESS but signiﬁ  cantly improved wakefulness on the MWT 
(Kingshott et al 2000). In patients with narcolepsy, a 24-week 
study which included three 2-week double-blind crossover 
periods, a 16-week open-label period, and a 2-week placebo-
controlled discontinuation period reported improvements in 
objectively determined wakefulness and subjective sleepi-
ness that were comparable to improvements shown in the 
9-week double-blind narcolepsy studies (Broughton et al 
1997; Moldofsky et al 2000).
Dosing
The recommended dose of modaﬁ  nil is 200 mg, to be 
taken once daily in the morning for patients with OSA Drug Design, Development and Therapy 2008:2 81
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or narcolepsy, or approximately 1 hour before the start 
of the work shift for patients with SWD (PROVIGIL® 
2007). Once daily doses of up to 400 mg have been 
well tolerated in randomized placebo-controlled studies. 
However, in the 9-week studies of narcolepsy patients, 
the 400-mg dose did not provide any beneﬁ  t beyond that 
shown for the 200-mg dose (US Modaﬁ  nil in Narcolepsy 
Multicenter Study Group 1998, 2000). While no clear dose 
response was observed in these placebo-controlled stud-
ies, a double-blind crossover study (n = 32) subsequently 
showed modaﬁ  nil 400 mg, taken once daily or as a split 
dose in the morning and at midday, was signiﬁ  cantly better 
at promoting wakefulness throughout the entire day than 
modaﬁ  nil 200 mg taken once-daily in the morning (both 
p   0.05) (Schwartz et al 2003b). The different ﬁ  ndings 
between the placebo-controlled studies and the crossover 
and parallel studies likely reﬂ  ect, at least in part, method-
ological differences in the execution and timing of sleep 
latency (MWT) testing protocols.
Dose-response effects were conﬁ  rmed and expanded in a 
subsequent analysis of 2 double-blind parallel group studies 
conducted in patients with narcolepsy (n = 56) (Schwartz et al 
2005). Modaﬁ  nil (200 mg once daily, 400 mg once daily, 400 
mg split-dose, and 600 mg split-dose) signiﬁ  cantly improved 
patients’ ability to sustain wakefulness compared with base-
line in a dose-dependent manner (p   0.05), with split-dose 
regimens producing signiﬁ  cantly greater improvement in 
MWT sleep latency than once-daily regimens in the afternoon 
and evening. These studies utilized an extended-day MWT, 
assessing the ability to remain awake at 2-hour intervals 
from 9 am to 9 pm. Another study showed modaﬁ  nil 600 
mg taken as split dose was signiﬁ  cantly more effective than 
modaﬁ  nil 400 mg once daily in improving late-day MWT 
sleep latency in patients with narcolepsy (n = 24) (Schwartz 
et al 2004). Others have reported modaﬁ  nil taken as a split 
dose in the morning and at midday (300–500 mg) did not 
adversely affect the quantity or quality of nighttime sleep in 
placebo-controlled, crossover studies (Billiard et al 1994; 
Broughton et al 1997; Moldofsky et al 2000). Dose escala-
tion or split-dose regimens may be important for patients 
who have satisfactory responses to modaﬁ  nil in the morning 
and afternoon but experience excessive sleepiness in the late 
afternoon or evening.
Abuse potential
Modaﬁ  nil is listed in Schedule IV of the Controlled Sub-
stances Act (PROVIGIL® 2007) because its potential for 
abuse is relatively low and may lead to limited physical 
or psychological dependence. In one preclinical study, the 
reinforcing and stimulant-discriminative effects of modaﬁ  nil 
were approximately 250 times less potent than amphetamine 
(Gold and Balster 1996). Another preclinical study reported 
modaﬁ  nil did not produce reinforcing or rewarding effects in 
stimulant-naïve animals (Deroche-Gamonet et al 2002). In 
clinical studies conducted in healthy volunteers with no cur-
rent or past history of substance abuse (Warot et al 1993) and 
in volunteers with histories of illicit drug use (Jasinski 2000; 
Rush et al 2002a, b), modaﬁ  nil could be distinguished from 
CNS stimulants on the basis of subjective effects (eg, elation or 
euphoria). Postmarketing surveillance (over 4 years) has found 
no generalized misuse of modaﬁ  nil, suggesting its potential for 
abuse on a large scale is limited (Myrick et al 2004).
Therapeutic considerations 
and clinical implications
Identiﬁ  cation of the underlying causes of excessive sleepi-
ness, including any sleep disorders, is critical to its successful 
management. Persistent or severe sleepiness that interferes 
with daily function and poses undue health burdens or 
safety risks may require pharmacologic therapy. Modaﬁ  nil 
may be prescribed for patients who have been evaluated for 
excessive sleepiness and have a diagnosis of OSA, SWD, 
or narcolepsy.
Across large-scale, double-blind studies, placebo-
controlled studies, modaﬁ  nil signiﬁ  cantly improved sleep 
latency on the MSLT and ability to maintain wakefulness on 
the MWT, improved overall clinical condition for sleepiness 
severity, and reduced patient-reported sleepiness on the ESS 
and KSS. Improvements in wakefulness were accompanied 
by improvements in behavioral alertness, functional status, 
and health-related quality of life. Modaﬁ  nil was well toler-
ated in the double-blind placebo-controlled studies and 
long-term studies. Noteworthy was the ﬁ  nding that modaﬁ  nil 
did not elevate mean blood pressure or heart rate relative to 
placebo in populations at risk for cardiovascular morbidity 
(ie, patients with OSA [Nieto et al 2000; Peppard et al 2000;] 
and night shift workers [Kawachi et al 1995; Tenkanen et al 
1997]) (Roth et al 2007).
The MSLT and MWT were primary measures of efﬁ  cacy 
in the double-blind placebo-controlled studies. As objective 
measures of sleep latency, the MSLT and the MWT are used 
in research and clinical settings. Of the two, the MSLT is 
used more widely and is considered to be a standard test for 
sleepiness by most sleep medicine specialists (Wise 2006). 
The strengths and weaknesses of the MSLT and MWT have 
been described in a recent review that evaluated their clinical Drug Design, Development and Therapy 2008:2 82
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usefulness (Arand et al 2005). While these tests do not appear 
to adequately discriminate between patients with sleep 
disorders and control subjects due in part to ﬂ  oor (MSLT) 
and ceiling (MWT) effects and to large standard deviations 
(Arand et al 2005), they effectively monitor changes caused 
by interventions that alter sleepiness or alertness (Arand et al 
2005). The MSLT in particular appears to be sensitive to 
changes in sleepiness across the 24-hour day and following 
long-term sleep debt or extension (Seidel et al 1984; Roehrs 
et al 1996). In addition, sleep latencies have been shown to 
reﬂ  ect circadian changes in studies that simulated night shift 
conditions (Arand et al 2005), suggesting responses occur as 
expected when sleep cycles are reversed (eg, for night shift 
workers). Whether establishing a diagnosis or evaluating 
a response to treatment, sleep latency test ﬁ  ndings should 
be interpreted within the context of other available medical 
information and testing (Arand et al 2005).
OSA is a common cause of excessive sleepiness, and 
residual sleepiness occurs in some patients who are oth-
erwise well treated for the underlying airway obstruction 
(Weaver et al 2007). While modaﬁ  nil reduces residual 
sleepiness in these patients, it does not treat the cause of 
OSA. It is therefore critical that patients adhere to inter-
ventions that directly address OSA-related pathology, such 
as CPAP therapy (Hirshkowitz and Black 2007). Weaver 
and colleagues established a relationship between hours of 
CPAP use during the night and achieving normal levels of 
daytime sleepiness and functioning; for example, thresholds 
above which further improvements were less likely for ESS 
was 4 hours, MSLT was 6 hours, and FOSQ was 7.5 hours 
(Weaver et al 2007). Despite concerns to the contrary (Pollak 
2003), modaﬁ  nil does not appear to adversely affect CPAP 
use. While a statistically signiﬁ  cant 12-minute reduction 
in nightly CPAP use was shown for patients receiving 
modaﬁ  nil compared with patients receiving placebo in a 
7-week, placebo-controlled crossover study of 30 patients 
(Kingshott et al 2000), modaﬁ  nil did not signiﬁ  cantly alter 
CPAP use in the large-scale, 4-week and 12-week double-
blind studies (Pack et al 2001; Black and Hirshkowitz 2005). 
In a 12-month follow-up to the 12-week study, mean nightly 
CPAP use declined by 34 minutes (p   0.0001 for the 
change from baseline) to a ﬁ  nal visit duration of 5.4 hours 
(Hirshkowitz and Black 2007). This duration is within the 
range of previously reported values for long-term CPAP use 
(4.3–6.5 hours) (Engleman et al 1994b; Reeves-Hoche et al 
1994; Krieger et al 1996; Pieters et al 1996; Collard et al 
1997). As a precaution, CPAP use should be encouraged 
and periodically assessed (Black and Hirshkowitz 2007; 
PROVIGIL® 2007). Difﬁ  culties with CPAP use, such as 
inadequate CPAP pressure and microarousals and sleep 
disruption caused by wearing the CPAP apparatus, should 
be addressed (Hirshkowitz and Black 2007).
Given the large number of individuals who work night 
shifts on a rotating or permanent basis or work early 
morning shifts (Beers 2000), recognition and diagnosis of 
SWD remains a pressing clinical issue. The adverse conse-
quences of shift work may be limited to those individuals 
who show a differential vulnerability to the effects of sleep 
loss (Drake et al 2004; Van Dongen et al 2004). Such indi-
viduals may be predisposed to developing SWD. Patients 
with SWD appear to be as sleepy during the night as 
patients with narcolepsy are during the day. Mean improve-
ments with modaﬁ  nil in MSLT sleep latency in patients 
with SWD were similar in magnitude to improvements 
reported for patients with narcolepsy who were treated 
with modaﬁ  nil (US Modaﬁ  nil in Narcolepsy Multicenter 
Study Group 1998, 2000) and to improvement reported 
in a meta-analysis of studies conducted in patients with 
OSA who were treated with CPAP therapy (0.74 min more 
than placebo) (Patel et al 2003). Although sleep latency 
was improved by nearly 2 minutes, it averaged less than 
5 minutes during the night, below what is considered to be 
normal during the daytime (Czeisler et al 2005). Similarly, 
mean sleep latencies have been reported to improve but 
not to normalize completely in patients with narcolepsy, 
either with modaﬁ  nil or CNS stimulants (US Modaﬁ  nil in 
Narcolepsy Multicenter Study Group 1998; Mitler 1991). 
Despite the lack of normalization, improvements across 
objective and subjective measures, including those for 
sleepiness, overall clinical condition, and behavioral alert-
ness (Czeisler et al 2005), together with improvements in 
functional status and health-related quality of life (Erman 
et al 2007) and diary data that showed proportionally fewer 
patients reporting accidents or near accidents (Czeisler 
et al 2005), suggest modaﬁ  nil administration is associated 
with clinically meaningful improvement in these patients. 
Because modaﬁ  nil may not completely eliminate excessive 
sleepiness in all patients, individuals should be advised to 
avoid activities that are potentially dangerous (eg, driving 
or operating machinery) or require appropriate levels of 
wakefulness until and unless modaﬁ  nil affords sufﬁ  cient 
wakefulness (PROVIGIL® 2007).
Modaﬁ  nil is an established ﬁ  rst-line therapy for exces-
sive sleepiness in patients with narcolepsy (Black et al 2005; 
Billiard et al 2006). An evaluation of adverse events and 
the potential for abuse must be made on an individual basis Drug Design, Development and Therapy 2008:2 83
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when prescribing modaﬁ  nil or other therapies for excessive 
sleepiness.
Conclusions
Multiple clinical studies indicate modaﬁ  nil is an efﬁ  cacious 
and well-tolerated therapy in the clinical management of 
excessive sleepiness in patients with OSA with ongoing 
sleepiness despite CPAP therapy, SWD, and narcolepsy. 
Long-term studies suggest continued efﬁ  cacy, with a low 
likelihood of tolerance and no adverse effects on scheduled 
sleep. Abuse liability studies show a limited potential for 
abuse.
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